GeoVax Labs shares are trading higher after the company received a BARDA Project NextGen award to conduct a Phase 2b clinical study evaluating its COVID-19 vaccine candidate, GEO-CM04S1. The direct award to GeoVax is approximately $24.3 million, which may increase to as much as $45 million.
Portfolio Pulse from Benzinga Newsdesk
GeoVax Labs shares are trading higher after receiving a BARDA Project NextGen award to conduct a Phase 2b clinical study for its COVID-19 vaccine candidate, GEO-CM04S1. The award is approximately $24.3 million, potentially increasing to $45 million.
June 18, 2024 | 7:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GeoVax Labs shares are trading higher after receiving a BARDA Project NextGen award to conduct a Phase 2b clinical study for its COVID-19 vaccine candidate, GEO-CM04S1. The award is approximately $24.3 million, potentially increasing to $45 million.
The significant funding from BARDA for the Phase 2b clinical study of GeoVax's COVID-19 vaccine candidate is a positive development. This financial support not only validates the potential of GEO-CM04S1 but also provides the necessary resources to advance its clinical trials, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100